研究单位：[1]Biotheus Inc.[2]Jilin Provincial Tumor Hospital[3]Affiliated Hospital of Nantong University,Nantong,Jiangsu,China[4]Jilin Cancer Hospital,Changchun,Jilin,China[5]The First Affiliated Hospital Of Ningbo University,Ningbo,Zhejiang,China[6]Binzhou Medical University Hospital,Binzhou,China[7]Hunan Cancer Hospital,Changsha,China[8]Sichuan Cancer Hospital,Chengdu,China[9]First People''s Hospital of Chenzhou,Chenzhou,China[10]The First Affiliated Hospital of Army Medical University,Chongqing,China[11]The Second Hospital of Dalian Medical University,Dalian,China[12]The First People''s Hospital of Foshan,Foshan,China[13]Fujian Cancer Hospital,Fuzhou,China[14]The Affiliated Hospital Of Guilin Medical University,Guilin,China[15]Zhejiang Cancer Hospital,Hangzhou,China[16]Harbin Medical University Cancer Hospital,Harbin,China[17]Anhui Province Hospital,Hefei,China[18]Shandong Cancer Institute,Jinan,China[19]Jingzhou First People''s Hospital,Jingzhou,China[20]Affiliated Hospital of Jining Medical University,Jining,China[21]Yunnan Cancer Hospital,Kunming,China[22]Liuzhou People''s Hospital,Liuzhou,China[23]The First Affiliated Hospital of Henan University of Science & Technology,Luoyang,China[24]Meizhou People''s Hospital,Meizhou,China[25]Mianyang Central Hospital,Mianyang,China[26]Jiangxi Cancer Hospital,Nanchang,China[27]The First Affiliated Hospital of Nanchang University,Nanchang,China[28]Nanchong Central Hospital,Nanchong,China[29]Jiangsu Province Hospital,Nanjing,China[30]Nanjing Drum-Tower Hospital,Nanjing,China[31]Guangxi Medical University Cancer Hospital,Nanning,China[32]Nanyang Central Hospital,Nanyang,China[33]Qujing NO.1 Hospital,Qujing,China[34]The Fourth Hospital of Hebei Medical University,Shijia Zhuang,China[35]Taizhou Enze Medical Center (group),Taizhou,China[36]Weifang NO.2 People''s Hospital,Weifang,China[37]Weihai Municipal Hospital,Weihai,China[38]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China[39]Zhongnan Hospital Of Wuhan University,Wuhan,China[40]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China[41]Xiangyang Central Hospital,Xiangyang,China[42]Xuzhou Central Hospital,Xuzhou,China[43]The Second People''s Hospital Of Yibin,Yibin,China[44]Yongzhou Central Hospital,Yongzhou,China[45]Yuncheng City Center Hospital,Yuncheng,China[46]Zhangzhou Municipal Hospital of Fujian Province,Zhangzhou,China[47]Zhoukou Central Hospital,Zhoukou,China
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
